Skip to main content

Table 2 Results of the sensitivity analysis

From: The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications

Outcome

Base case

Lesser effect of statins (HR 1.10)

Larger effect of statins (HR 1.58)

Statin cost + 25%

Statin cost − 25%

Additional CVD incidence

0.0134

0.0054

0.0307

0.0134

0.0134

Number needed to withhold

75

186

33

75

75

Total average cost of treatment

€208.67

€208.67

€208.67

€260.83

€156.50

Headroom at WTA = €0

€119.09

€119.09

€119.09

€148.86

€89.31

WTA at which headroom = €0

€15,614

€38,867

€6795

€19,518

€11,711

  1. HR hazard ratio for the effect of withholding statin treatment on cardiovascular disease, CVD cardiovascular disease, number needed to withhold = withholding treatment in this number of patients leads one additional cardiovascular disease event